El Afrit Mohamed Ali, Trojet Sonia, Mazlout Hela, Hamdouni Malek, Kraiem Abdelhafidh
Department of ophthalmology Habib Thameur Hospital Tunis.
Tunis Med. 2007 Nov;85(11):941-4.
Implantation of glaucoma drainage devices is currently considered as a good alternative to the traditional treatment of refractory glaucoma.
To evaluate the efficacy and safety of the Ahmed glaucoma valve implant in eyes with refractory glaucoma.
This retrospective study included 27 eyes from 27 patients with refractory glaucoma treated with the Ahmed glaucoma valve implant between February 1995 and January 2000. We reviewed the final intraocular pressure and incidence of complications in all patients.
The most common aetiology of refractory glaucoma was open-angle glaucoma (48.1%) followed by neovascular glaucoma (29.6%). After a mean follow-up of 35.74 months (range 9-52 months), the mean intraocular pressure decreased from 35.66 mm Hg before surgery to 14 mm Hg on the last follow-up visit after surgery. Thus, the procedure was successful in 69.23% of cases. Nine patients (33.33%) achieved reduced intraocular pressure without additional antiglaucomatous medication. Transient postoperative hypotony of < 5 mm Hg occurred in 14.8 % of patients. This was, with transient hyphaema, the most common postoperative complication.
The Ahmed glaucoma valve implant seems to be effective and safe for the management of refractory glaucoma. However, it is less effective in case of neovascular glaucoma.
目前，青光眼引流装置植入术被认为是难治性青光眼传统治疗方法的良好替代方案。
评估艾哈迈德青光眼引流阀植入术治疗难治性青光眼的有效性和安全性。
这项回顾性研究纳入了1995年2月至2000年1月期间接受艾哈迈德青光眼引流阀植入术治疗的27例难治性青光眼患者的27只眼。我们回顾了所有患者的最终眼压和并发症发生率。
难治性青光眼最常见的病因是开角型青光眼（48.1%），其次是新生血管性青光眼（29.6%）。平均随访35.74个月（范围9 - 52个月）后，平均眼压从术前的35.66 mmHg降至术后最后一次随访时的14 mmHg。因此，该手术在69.23%的病例中取得成功。9例患者（33.33%）眼压降低，无需额外使用抗青光眼药物。14.8%的患者术后出现短暂性眼压低于5 mmHg的低眼压。这与短暂性前房积血一样，是最常见的术后并发症。
艾哈迈德青光眼引流阀植入术治疗难治性青光眼似乎有效且安全。然而，对于新生血管性青光眼，其效果较差。
